Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 16, 2022; 10(29): 10655-10662
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10655
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10655
Patient characteristics | Case 1 | Case 2 | Lopes da Silva et al[21] | So et al[23] | Ifran et al[19] | Thomas[18] | Castro[20] | Martinez-Lopez et al[22] |
Age/Sex | 33/F | 61/M | 75/F | 29/M | 68/F | 71/F | 48/F | 19/F |
Thalassemic disorder | β-thalassemia minor | β-thalassemia minor | β-thalassemia minor | α- thalassemia | β-thalassemia minor | β-thalassemia minor | Sickle cell β-thalassemia minor | Delta-β-thalassemia minor |
MPN subtypes | Essential thrombocythemia | Primary myelofibrosis | Polycythemia vera | Primary myelofibrosis | Polycythemia vera | Polycythemia vera | Polycythemia vera | Polycythemia vera |
Splenomegaly | Yes | Yes | No | Yes | Yes | Yes | No | Yes |
Erythrocyte count | 5.26 × 1012/L | 4.21 × 1012/L | 9.0 × 1012/L | NR | 9.3 × 1012/L | 7.4 × 1012/L | 8 × 1012/L | NR |
Total blood hemoglobin | 106 g/L | 92 g/L | 154 g/L | 103 g/L | 155 g/L | 156 g/L | 144 g/L | 142 g/L |
White cell count | 10.9 × 109/L | 34.7 × 109/L | 13.5 × 109/L | Normal | 18.5 × 109/L | 14 × 109/L | 8 × 109/L | 22.5 × 109/L |
Platelet count | 1396× 109/L | 18 × 109/L | 500 × 109/L | Normal | NR | 486 × 109/L | 1233 × 109/L | 193 × 109/L |
MPN gene mutation | Negative | Type 1 (49-bp) deletion in exon 9 of CALR | JAK2 V617F | Type 1 (52-bp) deletion in exon 9 of CALR | Not assessed | Not assessed | Not assessed | JAK2 V617F |
Karyotype | 46, XX | 46, XY, t(11;18)(q13;p11.2), ins(17;17)(q21;q25q12) | NR | 46, XY, t(3;12)(p21;q13) | Not assessed | Not assessed | Not assessed | 46, XX |
Marrow biopsy | Proliferation of giant megakaryocytes with hyperlobulated nuclei | Reticulin graded as 4+ myelofibrosis | Panmyelosis | Stromal fibrosis and clusters of pleomorphic megakaryocytes | Not assessed | Not assessed | Increased megakaryocytes plus fibrosis | Prominent conspicuous megakaryocyte proliferation in clusters and minimal reticulin fibrosis |
Treatment | Hydroxyurea and interferon | Interferon→ruxolitinib | Hydroxyurea | NR | Phlebotomy | Phlebotomy | Busulfan→Phlebotomy→Mustard | Hydroxyurea and interferon→ruxolitinib |
- Citation: Xu NW, Li LJ. Myeloproliferative neoplasms complicated with β-thalassemia: Two case report. World J Clin Cases 2022; 10(29): 10655-10662
- URL: https://www.wjgnet.com/2307-8960/full/v10/i29/10655.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i29.10655